The impact of BNO 1030 on phagocytic activity of white blood cells in rats with type 1 diabetes mellitus

Main Article Content

Yu.V. Gavrylenko


Background. In the pathogenesis of type 1 diabetes mellitus (DM1) and many of its complications, an important place belongs to a violation of the functional capacity of the immune system, which is the subject of numerous studies. Considering the effectiveness of immunomodulating therapy for DM1 and its complications, one of the most important problems is the search for new effective and harmless immunocorrecting agents with high pharmacological activity. The purpose of this study was to evaluate the effect of the phytopreparation BNO 1030 on the phagocytic activity of blood leukocytes in rats with DM1. Materials and methods. Experimental DM1 in rats was induced by a single intraperitoneal injection of streptozotocin. The percentage of phagocytic cells and macrophage uptake of live fluorescent bacteria in the samples were determined using fluorescent live bacteria Escherichia coli. Results. The effect of the drug BNO 1030 on the phagocytic activity of white blood cells with DM1 in rats was investigated. Under hyperglycemia it was found changes in the redistribution of the main types of leukocytes, namely granulocytes and agranulocytes. The administration of the drug BNO 1030 to both control and diabetic animals resulted in an increase in the number of agranulocytes, which may indicate a modulating effect of the drug on the immune system of animals. Under these conditions, phagocytic activity of leukocytes was decreased as phagocytic number in group of diabetic rats was reduced by 42 % in comparison with group of control animals. BNO 1030 administration to diabetic rats caused an increase of phagocyte number by 24 % compared to the group of diabetic animals. These changes, in turn, are also accompanied by a decrease of phagocytic index as in diabetes, and when drug was administered to experimental groups, indicating disorders in nonspecific cellular immune system. Conclusions. BNO 1030 due to its immunomodulatory effect is effective in the treatment of DM1 and its comorbidity with other chronic diseases.

Article Details

How to Cite
Gavrylenko, Y. “The Impact of BNO 1030 on Phagocytic Activity of White Blood Cells in Rats With Type 1 Diabetes Mellitus”. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine), vol. 13, no. 5, Oct. 2017, pp. 374-9, doi:10.22141/2224-0721.13.5.2017.110028.
Experimental Endocrinology


Gavrilenko IuV. Features of upper respiratory tract lesions in children and adolescents with type 1 diabetes mellitus. Sovremennaya pediatriya. 2015;7(71):62-5; doi 10.15574/SP.2015.71.62 (in Russian).

Laiko AA, Gavrylenko IuV. Pattern of ENT-organ lesions in children with 1 type diabetes mellitus. Rinologiia. 2014;1:61-5. (in Ukrainian).

Pertseva NO, Martsynik EN, Chursinova TV. Features of insulin resistance in patients with long history of type 1 diabetes mellitus, methods of its correction. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2017;13(1):23-7. doi 10.22141/2224-0721.13.1.2017.96750. (in Russian).

Adeghate E, Schattner P, Dunn E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006 Nov;1084:1-29. doi: 10.1196/annals.1372.029.

Bicker H, Höflich C, Wolk K, Vogt K, Volk HD, Sabat R. A simple assay to measure phagocytosis of live bacteria. Clin Chem. 2008 May;54(5):911-5. doi: 10.1373/clinchem.2007.101337.

Casqueiro J, Casqueiro J, Alves C. Infections in patients with diabetes mellitus: A review of pathogenesis. Indian J Endocrinol Metab. 2012 Mar;16 Suppl 1:S27-36. doi: 10.4103/2230-8210.94253.

Chattopadhyay S, Ramanathan M, Das J, Bhattacharya SK. Animal models in experimental diabetes mellitus. Indian J Exp Biol. 1997 Nov;35(11):1141-5. PMID: 9567740.

Bilgic S, Aktas E, Salman F, et al. Intracytoplasmic cytokine levels and neutrophil functions in early clinical stage of type 1 diabetes. Diabetes Res Clin Pract. 2008 Jan;79(1):31-6. doi: 10.1016/j.diabres.2007.06.011.

Valle A, Giamporcaro GM, Scavini M, et al. Reduction of circulating neutrophils precedes and accompanies type 1 diabetes. Diabetes. 2013 Jun;62(6):2072-7. doi: 10.2337/db12-1345.

Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes. 2005 Dec;54 Suppl 2:S125-36. PMID: 16306330.

James S, Gallagher R, Dunbabin J, Perry L. Prevalence of vascular complications and factors predictive of their development in young adults with type 1 diabetes: systematic literature review. BMC Res Notes. 2014 Sep 2;7:593. doi: 10.1186/1756-0500-7-593.

Zhang C1, Yang J, Jennings LK. Leukocyte-derived myeloperoxidase amplifies high-glucose--induced endothelial dysfunction through interaction with high-glucose--stimulated, vascular non--leukocyte-derived reactive oxygen species. Diabetes. 2004 Nov;53(11):2950-9. PMID: 15504976.

Szablewski L, Sulima A. The structural and functional changes of blood cells and molecular components in diabetes mellitus. Biol Chem. 2017 Apr 1;398(4):411-423. doi: 10.1515/hsz-2016-0196.

Popov D. Endothelial cell dysfunction in hyperglycemia: Phenotypic change, intracellular signaling modification, ultrastructural alteration, and potential clinical outcomes. International Journal of Diabetes Mellitus. 2010;3:189-95. doi: 10.1016/j.ijdm.2010.09.002.

Molteni R, Fabbri M, Bender JR, Pardi R. Pathophysiology of leukocyte-tissue interactions. Curr Opin Cell Biol. 2006 Oct;18(5):491-8. doi: 10.1016/

Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care. 2001 Jun;24(6):1044-9. PMID: 11375368.